Hyperthermia payment boost
This article was originally published in The Gray Sheet
Executive Summary
CMS proposes to raise reimbursement for procedure codes applicable to BSD Medical's cancer treatment systems by 86% in the 2008 hospital outpatient payment 1proposal released July 16, according to the firm. CMS will finalize the rates in November, to be effective Jan. 1. BSD markets hyperthermia systems, which kill cancer cells with focused heat and may improve the effectiveness of radiation and chemotherapy by increasing blood flow. The firm filed a response July 30 to questions FDA had on its March PMA submission for the BSD-2000 deep hyperthermia system, providing new data from a Dutch study with 12-year follow-up of patients treated with advanced cervical cancer (2"The Gray Sheet" Jan. 9, 2006, p. 15)...
You may also be interested in...
BSD Medical Plans To File PMA For Cancer Therapy, Prepares Japanese Strategy
BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.